Special Issue "Hereditary Hemorrhagic Telangiectasia: Recent Advances and Future Challenges"
Deadline for manuscript submissions: closed (15 September 2020).
A printed edition of this Special Issue is available here.
Interests: HHT; pulmonary hypertension; (other) pulmonary vascular diseases
Interests: HHT; vascular biology; angiogenesis; endothelial cells; animal model; genetics; TGF-β signaling; endoglin
Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal heritable disease, leading to vascular malformations, ranging from mucocutaneous telangiectases to large arteriovenous malformations, which can occur in different organs. HHT is associated with a decreased quality of life and severe complications. If untreated, the disease leads to a decreased life expectancy. Recent years have brought advances in diagnosis and treatment, but not a cure for HHT. The exact molecular etiology is still unknown, but important steps in unravelling the mechanisms of disease haven been made.
This Special Issue aims to highlight not only the current knowledge regarding diagnosis and treatment of HHT, but also the newest insights in the molecular basis of HHT, because understanding the mechanisms of disease is essential for the development of new medicines or therapeutic strategies.
Dr. Hans-Jurgen Mager
Prof. Dr. Carmelo Bernabeu
Dr. Marco Post
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Hereditary Hemorrhagic Telangiectasia (HHT)
- Endoglin (ENG)
- arteriovenous malformations